Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gliatech Inc.

This article was originally published in The Gray Sheet

Executive Summary

Gliatech Inc.: Reports results of two clinical studies demonstrating the clinical effectiveness of the firm's Adcon-L and Adcon-T/N resorbable, barrier gels in "inhibiting postoperative adhesions and improving surgical outcome." Presented the week of Aug. 18 at the International Society of Orthopedic and Trauma Surgeons World Congress in Amsterdam, one study of 267 first-time lumbar discetomy patients shows that Adcon-L "significantly decreased peridural scar and improved patient outcome by reducing the incidence of activity related pain while performing typical activities of daily living." In a study involving 32 hand tenolysis procedures, patients treated with Adcon-T/N "showed a 118% greater improvement in digital range of motion compared to controls." Gliatech has clinical trials ongoing in the U.S. for the two gel-based products...

You may also be interested in...



GT Medical Technologies Raised $16M In Funding To Expand Brain Tumor Therapy

The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel